Can a Plant-Based pill help HIV patients quit smoking and drinking?

NCT ID NCT06790342

Not yet recruiting Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study in Nairobi, Kenya, will test whether a drug called cytisine, combined with counseling, can help 300 people with HIV quit smoking and reduce heavy drinking. Participants will receive either cytisine or a placebo, plus either intensive counseling or standard advice. The goal is to see if this combination improves health outcomes in a resource-limited setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytisine (a plant-based drug to help quit smoking and reduce alcohol use)
What this could lead to: If successful, this could provide an effective, low-cost treatment option for people with HIV who smoke and drink heavily, potentially reducing their risk of serious health problems.
What could go wrong: This is a Phase 3 trial, but it's still early to know if cytisine works better than standard advice. The results may not apply to all populations, and side effects from cytisine are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse HIV infectious disease nicotine dependence Tobacco Use Tobacco Use Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER HIV TOBACCO USE

Contacts and locations

Locations

Mathari National Teaching and Referral Hospital

Nairobi, Kenya
Riruta Health Centre

Nairobi, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.